Draft:Ron Adelman

Ron A. Adelman, MD, MPH, MBA, FACS, FARVO, is an ophthalmologist and academic, known for his contributions to retinal and macular disease research and surgery. He currently serves as the Chair of the Department of Ophthalmology at the Mayo Clinic in Jacksonville, Florida, effective March 1, 2024.

Early Life and Education
Adelman completed his undergraduate and medical education, followed by a Master of Public Health (MPH) from the University of California, Berkeley. He furthered his education with a Master of Business Administration (MBA) from the Yale School of Management. His medical training includes an ophthalmology residency and a fellowship in retinal surgery at Harvard Medical School, where he received numerous awards, including the Fellow of the Year in 2000 and the Club Vit Fellow Research Award.

Academic and Medical Positions
Adelman joined the Yale School of Medicine in 2001, initially as an Assistant Professor. He rose to the rank of Professor and served as the Interim Chair of the Department of Ophthalmology and Visual Science from 2014 to 2016. He also held the position of Vice Chair of Academics and was the Director of the Retina and Macula Service at Yale.

Leadership and Contributions
Adelman has held significant leadership roles in various medical societies. He was the President of the Connecticut State Medical Society (CSMS) 2021-2022, the Connecticut Society of Eye Physicians and Surgeons (CSEP) 2014-2016, and the New Haven County Medical Association (NHCMA) 2017-2019. Nationally and internationally, he served as the Scientific Director of the European VitreoRetinal Society (EVRS) since 2014, a councilor of the American Academy of Ophthalmology (AAO), and the CME Chair of the Association for Research in Vision and Ophthalmology (ARVO). Additionally, he is an examiner for the American Board of Ophthalmology.

Research and Innovations
Adelman has been at the forefront of research in macular and retinal diseases. He is the co-first author of the original laboratory paper on ranibizumab (Lucentis), the first effective treatment for wet macular degeneration. He has introduced novel surgeries for macular holes that are now utilized globally and has described several new disorders. His recent work includes pioneering research on stem cells to re-engineer ocular tissues.

Publications and Editorial Work
With over 500 publications and abstracts, Adelman has made substantial contributions to ophthalmology literature. He serves on the editorial boards of eight scientific journals, including the American Journal of Ophthalmology.

Awards and Honors
Throughout his career, Adelman has received numerous accolades: - Senior Honor Award from the American Society of Retina Specialists - Senior Achievement Award from the American Academy of Ophthalmology - Gold Fellow of the Association for Research in Vision and Ophthalmology - M. Bruce Shields Teaching Award - "Knight of the Blind" by the Lions of Connecticut for his outstanding work globally and throughout the state

Teaching and Mentorship
Adelman is recognized for his commitment to education, having received the Bruce Shields Teaching Award and served as a thesis advisor for over 20 Yale medical students. His mentorship has influenced many students, residents, and faculty members.